hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.5599/admet.514

Subcellular localization of several structurally different tyrosine kinase inhibitors

Richard J. Honeywell ; Dept of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Sarina M. Hitzerd ; Dept of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
G.A.M. Kathmann ; Dept of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Godefridus J. Peters ; Dept of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

Puni tekst: engleski, pdf (475 KB) str. 258-266 preuzimanja: 159* citiraj
APA 6th Edition
Honeywell, R.J., Hitzerd, S.M., Kathmann, G.A.M. i Peters, G.J. (2018). Subcellular localization of several structurally different tyrosine kinase inhibitors. ADMET and DMPK, 6 (3), 258-266. https://doi.org/10.5599/admet.514
MLA 8th Edition
Honeywell, Richard J., et al. "Subcellular localization of several structurally different tyrosine kinase inhibitors." ADMET and DMPK, vol. 6, br. 3, 2018, str. 258-266. https://doi.org/10.5599/admet.514. Citirano 22.11.2019.
Chicago 17th Edition
Honeywell, Richard J., Sarina M. Hitzerd, G.A.M. Kathmann i Godefridus J. Peters. "Subcellular localization of several structurally different tyrosine kinase inhibitors." ADMET and DMPK 6, br. 3 (2018): 258-266. https://doi.org/10.5599/admet.514
Harvard
Honeywell, R.J., et al. (2018). 'Subcellular localization of several structurally different tyrosine kinase inhibitors', ADMET and DMPK, 6(3), str. 258-266. https://doi.org/10.5599/admet.514
Vancouver
Honeywell RJ, Hitzerd SM, Kathmann GAM, Peters GJ. Subcellular localization of several structurally different tyrosine kinase inhibitors. ADMET and DMPK [Internet]. 2018 [pristupljeno 22.11.2019.];6(3):258-266. https://doi.org/10.5599/admet.514
IEEE
R.J. Honeywell, S.M. Hitzerd, G.A.M. Kathmann i G.J. Peters, "Subcellular localization of several structurally different tyrosine kinase inhibitors", ADMET and DMPK, vol.6, br. 3, str. 258-266, 2018. [Online]. https://doi.org/10.5599/admet.514

Sažetak
Protein tyrosine kinases form an important target for a new class of anticancer drugs, the tyrosine kinase inhibitors (TKIs). Recently we demonstrated that sunitinib, an inhibitor of the membrane-associated vascular endothelial growth factor receptor (VEGFR), is trapped in lysosomes which isolates the drug from its intended target. Therefore we investigated whether this also holds for other TKIs, targeted against different protein kinases. For this purpose we used the ProteoExtractR kit, which enables a subcellular extraction separating cellular proteins into four distinct fractions covering the cytosol, membranes and membrane organelles (including lysosomes), nuclear proteins and the cytoskeleton. Since TKIs are 98-100 % protein bound we used this property to study their subcellular distribution and used Caco-2 cells as a model. As expected after 2 hours exposure sunitinib was trapped in cytosol (58 %) and organelles (42 % including lysosomes). Crizotinib, an inhibitor of ALK-EML4, showed a similar distribution. However, erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR) showed a very low cellular accumulation and was limited to the organelle fraction. In contrast, the other EGFR inhibitor, gefitinib was predominantly located in the cytosolic (39 %) and membrane fraction (44 %). Sorafenib, another VEGFR inhibitor was predominantly located in the organelle fraction (85 %) and cytosol (15 %) after 2 hours, while after 24 hours distribution decreased (9.9 fold) with a slight shift. Dasatinib, an inhibitor of BCR-Abl was located only in the cytosol (100 %). In general localization after 24 hours was comparable, albeit several small changes were seen. In conclusion protein fractionation with the ProteoExtractR Subcellular Proteome Extraction kit demonstrated large differences in TKI levels in various cellular organelles, with a pattern in agreement with lysosomal accumulation of sunitinib.

Ključne riječi
tyrosine kinase inhibitors; lysosomal accumulation; subcellular distribution; sunitinib; erlotinib; dasatinib

Hrčak ID: 205906

URI
https://hrcak.srce.hr/205906

Posjeta: 234 *